# A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct07579234/  
OnCo record `nct07579234` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing F182112 in multiple myeloma, now recruiting.

## Summary

A Multicenter, Randomised, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT07579234, led by Shandong New Time Pharmaceutical, and recruiting on the registry. Official title: Phase III Clinical Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma. Planned enrolment is 261 participants (estimated). The study started in 2026-01-25 and primary completion is expected in 2029-01-25. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07579234
- Phase: 3
- Setting: Phase III Clinical Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma
- Sponsor: Shandong New Time Pharmaceutical
- Enrolled: 261

## Sources

- ClinicalTrials.gov NCT07579234: https://clinicaltrials.gov/study/NCT07579234

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- drugs: [F182112](https://onco.cc/drugs/f182112/)
- companies: [Shandong New Time Pharmaceutical](https://onco.cc/companies/shandong-new-time-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct07579234.json